This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
It was certainly not our intention to raise false hope for anyone concerned with the treatment of postherpetic neuralgia, specifically pertaining to the availability of AMP for use. Our article was clearly placed in the category of PRELIMINARY COMMUNICATION, the results reported were clearly investigational clinical trials, and no recommendations for immediate and widespread use of AMP were made. Drug availability, information on supplies, and trade names of products are not commonly included in this type of a communication, although we can sympathize with patients seeking immediate relief from their neuralgia even from the drug still undergoing investigational trials.With any new or investigational agent being evaluated for human use, drug safety and therapeutic effectiveness will have to be documented before widespread administration can be warranted.
Sklar SH, Alexander EJ, Blue WT, Bodian CA. False Hope on Drug Availability-Reply. JAMA. 1985;254(14):1905. doi:10.1001/jama.1985.03360140057023
Customize your JAMA Network experience by selecting one or more topics from the list below.